Kevin Sloan

Senior Director, Program Leader & Head of Early Development Program Management at Alnylam Pharmaceuticals - Cambridge, Massachusetts, US

Kevin Sloan's Colleagues at Alnylam Pharmaceuticals
Cynthia Courtney

Sr Director, Regulatory Affairs, Advertising, Promotion and Labeling

Contact Cynthia Courtney

Natacha Miller

Regulatory Affairs, Global Labeling

Contact Natacha Miller

Jennifer Backo

Director, US Advertising & Promotion, Regulatory Affairs

Contact Jennifer Backo

Taryn Catlin

Director, Early Stage Quality

Contact Taryn Catlin

Gerard Walsh

Director Supply Chain Technical Services

Contact Gerard Walsh

View All Kevin Sloan's Colleagues
Kevin Sloan's Contact Details
HQ
(617) 551-8200
Location
Cambridge, Massachusetts, United States
Company
Alnylam Pharmaceuticals
Kevin Sloan's Company Details
Alnylam Pharmaceuticals logo, Alnylam Pharmaceuticals contact details

Alnylam Pharmaceuticals

Cambridge, Massachusetts, US • 2460 Employees
SaaS

ALNYLAM IS LEADING THE RNAi REVOLUTION™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-23), Science Magazine (2018-23), Fast Company (Best Workplaces for Innovators 2020-23) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861

Rna Therapeutics Innovative Treatments Ocular Disease Treatment
Details about Alnylam Pharmaceuticals
Frequently Asked Questions about Kevin Sloan
Kevin Sloan currently works for Alnylam Pharmaceuticals.
Kevin Sloan's role at Alnylam Pharmaceuticals is Senior Director, Program Leader & Head of Early Development Program Management.
Kevin Sloan's email address is ***@alnylam.com. To view Kevin Sloan's full email address, please signup to ConnectPlex.
Kevin Sloan works in the SaaS industry.
Kevin Sloan's colleagues at Alnylam Pharmaceuticals are Erin Rouleau, David Golding, Cynthia Courtney, Natacha Miller, Jennifer Backo, Taryn Catlin, Gerard Walsh and others.
Kevin Sloan's phone number is (617) 551-8200
See more information about Kevin Sloan